Tuesday August 20, 2013 0 commentsBOULDER - Agilent Technologies Inc. (NYSE: A) and SomaLogic Inc. have entered into an agreement to expand access to SomaLogic's unbiased protein biomarker discovery platform, the companies announced.
The companies said they will initially place SomaLogic's SOMAscan proteomic assay, which uses custom Agilent microarrays in its workflow, in select academic and contract research centers.
Although the SOMAscan assay is already available to researchers directly from SomaLogic as a service, this planned rollout is aimed at meeting the rapidly growing demand for access to SomaLogic's highly multiplexed, cost-effective proteomic analyses, SomaLogic said.
"This agreement will greatly enhance our current microarray offerings by expanding them into the rapidly growing proteomics market," said Jacob Thaysen, Agilent's VP and GM of its Genomics Solutions Division.
"SomaLogic's cutting-edge proteomic technology makes them an ideal partner for us to increase our presence in this growing market."
"Agilent's custom microarrays have been a critical element in our development of the SOMAscan assay over the past several years," said Larry Gold, SomaLogic chairman and CEO.
"We are delighted that our partnership is expanding to make the technology even more accessible to researchers everywhere."
Terms of the agreement were not disclosed.
For more information, visit www.somalogic.com.